Drug intelligence / Profile preview

GlucoThera Low Sodium

Development stage: Unknown
Lead developer: Iperboreal Pharma
Administration: Intraperitoneal

Overview

GlucoThera Low Sodium is a low-sodium, glucose-based peritoneal dialysis solution developed by Iperboreal Pharma for patients with End-Stage Renal Disease (ESRD). It is designed for use in both continuous ambulatory peritoneal dialysis (CAPD) and automated peritoneal dialysis (APD). The solution functions as an osmotic agent, utilizing glucose to drive ultrafiltration and solute removal across the peritoneal membrane. Unlike standard glucose-based solutions, GlucoThera Low Sodium features a reduced sodium concentration in the dialysate, which is intended to help manage sodium balance and potentially reduce systemic sodium loading in dialysis patients. It is part of Iperboreal Pharma's portfolio of more biocompatible peritoneal dialysis solutions.

Brand names: GlucoThera Low Sodium

Beyond the preview

Go deeper on GlucoThera Low Sodium.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GlucoThera Low Sodium.

Explore the full profile